$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009318 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$79.44M	$93.25M
YoY Change	-14.81%	43.84%
Cost Of Revenue	$1.268M	$1.878M
YoY Change	-32.48%	51.45%
Gross Profit	$78.17M	$91.37M
YoY Change	-14.45%	43.69%
Gross Profit Margin	98.4%	97.99%
Selling, General & Admin	$29.51M	$27.54M
YoY Change	7.17%	12.9%
% of Gross Profit	37.75%	30.14%
Research & Development	$29.02M	$26.12M
YoY Change	11.1%	29.04%
% of Gross Profit	37.13%	28.59%
Depreciation & Amortization	$254.0K	$238.0K
YoY Change	6.72%	147.92%
% of Gross Profit	0.32%	0.26%
Operating Expenses	$58.53M	$53.66M
YoY Change	9.08%	20.22%
Operating Profit	$19.64M	$37.71M
YoY Change	-47.93%	98.94%
Interest Expense	$280.0K	$1.470M
YoY Change	-80.95%	33.64%
% of Operating Profit	1.43%	3.9%
Other Income/Expense, Net	$275.0K	$1.471M
YoY Change	-81.31%	34.09%
Pretax Income	$19.91M	$39.18M
YoY Change	-49.18%	95.39%
Income Tax	-$3.600M	$9.100M
% Of Pretax Income	-18.08%	23.22%
Net Earnings	$23.47M	$30.07M
YoY Change	-21.95%	64.52%
Net Earnings / Revenue	29.54%	32.24%
Basic Earnings Per Share	$0.20	$0.26
Diluted Earnings Per Share	$0.18	$0.25
COMMON SHARES
Basic Shares Outstanding	116.8M shares	114.6M shares
Diluted Shares Outstanding	129.7M shares	122.2M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$373.0M	$307.3M
YoY Change	21.38%	64.42%
Cash & Equivalents	$52.38M	$84.48M
Short-Term Investments	$320.6M	$222.8M
Other Short-Term Assets	$9.500M	$5.700M
YoY Change	66.67%	0.0%
Inventory	$4.948M	$5.084M
Prepaid Expenses
Receivables	$22.20M	$26.68M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$409.6M	$344.8M
YoY Change	18.81%	58.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.481M	$880.0K
YoY Change	68.3%	-4.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$81.80M	$41.70M
YoY Change	96.16%	44.79%
Other Assets	$5.030M	$3.441M
YoY Change	46.18%	4488.0%
Total Long-Term Assets	$142.8M	$100.7M
YoY Change	41.76%	-2.54%
TOTAL ASSETS
Total Short-Term Assets	$409.6M	$344.8M
Total Long-Term Assets	$142.8M	$100.7M
Total Assets	$552.4M	$445.5M
YoY Change	24.0%	39.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.969M	$4.976M
YoY Change	40.05%	-46.67%
Accrued Expenses	$18.00M	$19.59M
YoY Change	-8.12%	4.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.60M	$34.08M
YoY Change	19.15%	-0.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.000M	$1.900M
YoY Change	-47.37%	850.0%
Total Long-Term Liabilities	$1.000M	$1.900M
YoY Change	-47.37%	850.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.60M	$34.08M
Total Long-Term Liabilities	$1.000M	$1.900M
Total Liabilities	$41.60M	$36.01M
YoY Change	15.53%	4.49%
SHAREHOLDERS EQUITY
Retained Earnings	$105.9M	$6.510M
YoY Change	1527.05%	-106.55%
Common Stock	$536.5M	$465.6M
YoY Change	15.21%	8.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$510.8M	$409.5M
YoY Change
Total Liabilities & Shareholders Equity	$552.4M	$445.5M
YoY Change	24.0%	39.12%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	$23.47M	$30.07M
YoY Change	-21.95%	64.52%
Depreciation, Depletion And Amortization	$254.0K	$238.0K
YoY Change	6.72%	147.92%
Cash From Operating Activities	$25.42M	$33.27M
YoY Change	-23.59%	40.49%
INVESTING ACTIVITIES
Capital Expenditures	$126.0K	$42.00K
YoY Change	200.0%	-83.66%
Acquisitions
YoY Change
Other Investing Activities	-$3.200M	$19.80M
YoY Change	-116.16%	-19900.0%
Cash From Investing Activities	-$3.284M	$19.73M
YoY Change	-116.64%	-5477.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$33.54M	$275.0K
YoY Change	12096.73%	-97.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$45.95M	$205.0K
YoY Change	-22513.17%	-101.34%
NET CHANGE
Cash From Operating Activities	$25.42M	$33.27M
Cash From Investing Activities	-$3.284M	$19.73M
Cash From Financing Activities	-$45.95M	$205.0K
Net Change In Cash	-$23.81M	$53.21M
YoY Change	-144.75%	563.03%
FREE CASH FLOW
Cash From Operating Activities	$25.42M	$33.27M
Capital Expenditures	$126.0K	$42.00K
Free Cash Flow	$25.30M	$33.23M
YoY Change	-23.87%	41.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	000-50679
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	CORCEPT THERAPEUTICS INC
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001088856
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0487658
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	149 Commonwealth Drive
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
CY2021Q1	dei	City Area Code CityAreaCode	650
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	327-3270
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021Q1	dei	Trading Symbol TradingSymbol	CORT
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	116630692	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52381000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76190000	USD
CY2021Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	320578000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	364506000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22200000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26198000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	4948000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4910000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9517000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6697000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	409624000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	16247000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	478501000	USD
CY2021Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	15384000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2020000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2509000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1481000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1675000	USD
CY2021Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	81834000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	36196000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5030000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	37025000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	31603000	USD
CY2021Q1	us-gaap	Assets Assets	552398000	USD
CY2020Q4	us-gaap	Assets Assets	571731000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6969000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10554000	USD
CY2021Q1	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13566000	USD
CY2020Q4	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13704000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17999000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21186000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2067000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2050000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	40601000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47494000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	501000	USD
CY2021Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	995000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	398000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	41596000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	48393000	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	124000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	122000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	536363000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	516140000	USD
CY2021Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	131855000	USD
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	75795000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	249000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	415000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	105921000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	82456000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	510802000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	523338000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	552398000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	571731000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79437000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	93247000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1268000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1878000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29022000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26123000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29509000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27535000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	59799000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	55536000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	19638000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	37711000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	275000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1471000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	19913000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	39182000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3552000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9117000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	30065000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	61000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-20000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-192000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	61000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	26000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	23299000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	30114000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116818000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114575000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129668000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	122226000	shares
CY2021Q1	us-gaap	Profit Loss ProfitLoss	23465000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	30065000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10101000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7918000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5360000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5095000	USD
CY2021Q1	cort	Accretion Expense Income AccretionExpenseIncome	1194000	USD
CY2020Q1	cort	Accretion Expense Income AccretionExpenseIncome	-177000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	254000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	238000	USD
CY2021Q1	cort	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	489000	USD
CY2020Q1	cort	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	364000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3998000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6756000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-866000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1328000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2850000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-358000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3493000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2600000	USD
CY2021Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	-138000	USD
CY2020Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	1461000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3217000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3676000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	597000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	USD
CY2021Q1	cort	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-484000	USD
CY2020Q1	cort	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-349000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25422000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	33269000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	124230000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	68245000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	127388000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48469000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3284000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19734000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4038000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	480000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	33541000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	275000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16444000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-45947000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	371182000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	480000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	205000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23809000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53208000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76190000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31269000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52381000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84477000	USD
CY2021Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	6045000	USD
CY2020Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	0	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	275000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7988000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	49000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	30065000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	409489000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	523338000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10083000	USD
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33540000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	22520000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10142000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-166000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	510802000	USD
CY2021Q1	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	4	series
CY2021Q1	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	0	USD
CY2020Q4	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	1685000	USD
CY2021Q1	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	14889000	USD
CY2020Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	12916000	USD
CY2021Q1	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	5443000	USD
CY2020Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	6556000	USD
CY2021Q1	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	20332000	USD
CY2020Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	21157000	USD
CY2021Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	15384000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	16247000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	4948000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4910000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3588000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3528000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2107000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1853000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1481000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1675000	USD
CY2021Q1	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	11785000	USD
CY2020Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	9412000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3992000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10144000	USD
CY2021Q1	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	713000	USD
CY2020Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	612000	USD
CY2021Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	610000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	665000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	585000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	151000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	314000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	202000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17999000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21186000	USD
CY2021Q1	cort	Deposits For Clinical Trials DepositsForClinicalTrials	4800000	USD
CY2020Q4	cort	Deposits For Clinical Trials DepositsForClinicalTrials	4800000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	432952000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	451226000	USD
CY2021Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	1700000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1300000	USD
CY2021Q1	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P2Y
CY2021Q1	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P7M
CY2021Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2021Q1	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
CY2021Q1	cort	Number Of Stock Option Plans NumberOfStockOptionPlans	2	stockOptionPlan
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1800000	shares
CY2021Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	800000	shares
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16400000	USD
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000	shares
CY2021Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	7900000	shares
CY2020Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	5200000	shares
CY2021Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	41000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	70000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10142000	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7988000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	30065000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116818000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114575000	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	12850000	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7651000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129668000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	122226000	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26800000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27000000.0	shares
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9100000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	200000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6200000	USD
CY2021Q1	cort	Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance	1500000	USD

Files In Submission

Name	View Source	Status
0001628280-21-009318-index-headers.html	Edgar Link	pending
0001628280-21-009318-index.html	Edgar Link	pending
0001628280-21-009318.txt	Edgar Link	pending
0001628280-21-009318-xbrl.zip	Edgar Link	pending
cort-20210331.htm	Edgar Link	pending
cort-20210331.xsd	Edgar Link	pending
cort-20210331_cal.xml	Edgar Link	unprocessable
cort-20210331_def.xml	Edgar Link	unprocessable
cort-20210331_htm.xml	Edgar Link	completed
cort-20210331_lab.xml	Edgar Link	unprocessable
cort-20210331_pre.xml	Edgar Link	unprocessable
cort33121ex101.htm	Edgar Link	pending
cort33121ex102.htm	Edgar Link	pending
cort33121ex311.htm	Edgar Link	pending
cort33121ex312.htm	Edgar Link	pending
cort33121ex321.htm	Edgar Link	pending
cort33121ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2021 Q1 Form 10-Q Financial Statement

#000162828021009318 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2021 Q1 Form 10-Q Financial Statement

#000162828021009318 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort